Meeting
2022 ASCO Annual Meeting
Phase 2 study of tarlatamab, a DLL3-targeting, half life–extended, bispecific T-cell engager (HLE BiTE) immuno-oncology therapy, in relapsed/refractory small cell lung cancer (SCLC).
Authors
Suresh S. Ramalingam
Winship Cancer Institute of Emory University, Atlanta, GA
Suresh S. Ramalingam , Myung-Ju Ahn , Hiroaki Akamatsu , Fiona Helen Blackhall , Hossein Borghaei , Horst-Dieter Hummel , Melissa Lynne Johnson , Martin Reck , Yiran Zhang , Danielle Jandial , Sunfa Cheng , Luis G. Paz-Ares
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT05060016
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS8603)
DOI
10.1200/JCO.2022.40.16_suppl.TPS8603
Abstract #
TPS8603
Poster Bd #
222a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase 1b study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune-oncology therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).
First Author: Rahul Raj Aggarwal
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase 1b study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).
First Author: Rahul Raj Aggarwal
Poster
2020 ASCO Virtual Scientific Program
Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC).
First Author: Taofeek Kunle Owonikoko
Poster
2023 ASCO Annual Meeting
Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304).
First Author: Luis G. Paz-Ares